Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
On September 17, 2026, Mankind Pharma Limited announced that shareholders approved the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director for a five-year term starting August 10, 2026. The approval was based on remote e-voting, which concluded on September 17, 2026. The resolution received 99.9627% of the votes polled in favor, with 396,056,973 votes in favor and 147,811 votes against.
Mankind Pharma's management was scheduled to participate in investor meetings in mid-September 2026. These included the Jefferies 5th India Forum in Gurgaon on September 17, 2026, the Health Care Forum in Mumbai on September 18, 2026, and the J.P. Morgan India Conference in Mumbai on September 21, 2026. These events involved one-on-one or group meetings with analysts and institutional investors.
As of September 18, 2026, the daily trend for Mankind Pharma indicates a bearish SuperTrend direction with a value of 2401.69. The closing price was ₹2300.7. Key support levels are identified at ₹2283.63 and ₹2274.07, while resistance levels are noted at ₹2325.17 and ₹2350.33.
On September 7, 2026, members of Bharat Serums and Vaccines Limited (BSVL), a wholly owned subsidiary of Mankind Pharma Limited, approved the voluntary liquidation of BSVL. This decision is subject to creditor approval under the Insolvency and Bankruptcy Code, 2016.
As of 18 Sept 2026, 03:30 pm
Showing 3 of 5 candles
Recent drawdown or price variability is high enough to warrant closer monitoring.
Primary driver: Price remains materially below a previous peak
Trading activity was substantially higher than usual and the price closed lower.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | PEAK₹4,030.59 crore | ₹3,442.93 crore | ₹3,567.20 crore | ₹3,697.16 crore | ₹3,570.35 crore |
| Profit Before Exceptional Items And Tax | PEAK₹765.51 crore | ₹679.34 crore | ₹612.38 crore | ₹621.70 crore | ₹537.32 crore |
| Profit Before Tax | PEAK₹765.51 crore | ₹656.18 crore | ₹505.79 crore | ₹621.70 crore | ₹537.32 crore |
| Profit Loss For Period | PEAK₹574.09 crore | ₹559.42 crore | ₹413.88 crore | ₹520.18 crore | ₹444.62 crore |
| Finance Costs | ₹109.98 crore | ₹141.75 crore | ₹157.20 crore | ₹169.68 crore | PEAK₹170.65 crore |
| Other Expenses | PEAK₹962.63 crore | ₹803.08 crore | ₹846.07 crore | ₹888.48 crore | ₹886.58 crore |
Mankind Pharma reported higher revenue and a sharp increase in profit before tax during the first quarter of FY2026‑27. The improvement in pre‑tax earnings was helped by a substantial drop in finance costs. However, a much larger tax expense limited the rise in net profit, which grew moderately from a year earlier and only slightly from the previous quarter.
Finance costs fell to ₹109.98 crore, a decline of 35.6% year‑on‑year from ₹170.65 crore and 22.4% sequentially from ₹141.75 crore. This reduction contributed directly to the higher pre‑tax profit.
Other expenses increased to ₹962.63 crore from ₹886.58 crore a year earlier, a rise of 8.6%. As a share of revenue, other expenses declined from 24.8% to 23.9%, so these costs grew at a slower pace than revenue.
Basic earnings per share were ₹13.76, up from ₹10.62 a year earlier and from ₹13.44 sequentially. Diluted earnings per share showed a similar pattern.
Comprehensive income for the period was ₹553.78 crore, up 24.8% year‑on‑year from ₹443.86 crore but down 5.9% sequentially from ₹588.36 crore. The sequential decline in comprehensive income, while net profit rose, indicates that other comprehensive income was negative in the quarter.
Mankind Pharma’s revenue increased, and pre‑tax profit grew sharply with the help of lower finance costs. However, a significantly higher tax expense reduced the amount of that gain that reached the bottom line. Net profit rose year‑on‑year but showed only a modest sequential increase as the effective tax rate moved from 17.8% to 25.5%.
Exchange disclosures and regulatory announcements for Mankind Pharma.
Shareholders of Mankind Pharma Limited approved the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director for a five-year term commencing August 10, 2026, via a special resolution passed through remote e-voting. The e-voting period ran from August 19, 2026, to September 17, 2026, and the resolution was passed with 99.9627% of votes polled in favor (396,056,973 votes) and 0.0373% against (147,811 votes).
Mankind Pharma Limited has informed the Exchange about ESG Rating |SUBJECT: General Updates
Mankind Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
Mankind Pharma Limited announced on September 11, 2026, that its management will attend three investor meetings scheduled for mid-September 2026. The company is set to participate in the Jefferies 5th India Forum in Gurgaon on September 17, the Health Care Forum in Mumbai on September 18, and the J.P. Morgan India Conference in Mumbai on September 21. These events are designated as one-on-one or group meetings with various analysts and institutional investors.
On September 7, 2026, the members of Bharat Serums and Vaccines Limited (BSVL), a wholly owned subsidiary of Mankind Pharma Limited, approved the voluntary liquidation of BSVL at an Extraordinary General Meeting, subject to creditor approval under the Insolvency and Bankruptcy Code, 2016.
On 2026-09-01, Mankind Pharma Limited allotted 49,112 equity shares under ESOP/ESPS, increasing paid-up share capital from ₹412,995,978 to ₹413,045,090 and shares from 412,995,978 to 413,045,090. The board approval for issuance was on 2022-07-19, with no prior disclosure as the company was not listed at that time.
On September 1, 2026, Mankind Pharma Limited's Nomination and Remuneration Committee allotted 49,112 equity shares (face value ₹1 each) to eligible employees under the Mankind Employee Stock Option Plan 2022, at an exercise price of ₹860.00 per share. The paid-up share capital increased from 41,29,95,978 to 41,30,45,090 equity shares. The allotted shares rank pari-passu with existing shares.
On August 26, 2026, the Board of Mankind Pharma Limited approved the voluntary liquidation of its wholly owned subsidiary Bharat Serums and Vaccines Limited (BSVL) to consolidate BSVL's business into the parent company on a going concern basis. The Company holds 96% of BSVL directly, with the remaining 4% held by Appian Properties Private Limited, another wholly owned subsidiary. Appian will receive cash equivalent to 4% of BSVL's fair value as per an independent valuation. The liquidation is subject to compliance with the Insolvency and Bankruptcy Code and receipt of necessary approvals and licenses.
Recent market and company developments associated with Mankind Pharma.
The move is aimed at reducing compliance requirements for low-risk products that health authorities want to make more widely available.
The Feds indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction.
India Business News: Stock market recommendations: PN Gadgil Jewellers, Mankind Pharma, and BEML are the top stocks recommended by Ganesh Dongre, Senior Manager - Technica.
The Indian stock market is set for a flat opening on 16 September, following a decline in global markets. The Sensex fell 777.94 points, while the Nifty 50 dropped 279.50 points, influenced by rising crude oil prices and inflation concerns amid geopolitical tensions.
The move is significant for India’s generic injectable industry, where manufacturing lapses can pose a more immediate risk to patients than defects in medicines taken orally.
Mankind Pharma Ltd is quoting at Rs 2280.2, down 1.25% on the day as on 13:19 IST on the NSE. The stock tumbled 12.59% in last one year as compared to a 5.73% slide in NIFTY and a 20.8% spurt in the Nifty Pharma index.
Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Capital Healthcare Fund exit its entire holding. Linux Laboratories focuses on central nervous system therapies and has a strong brand portfolio. The company anticipates robust revenue and Ebitda growth in the coming years. This acquisition highlights continued private equity interest in India's pharmaceutical sector.
Indian equity markets ended lower on August 31, responding to prevailing global economic dynamics. A modest decline in the Nifty50 index brought it below essential moving averages. Key corporate updates emerged, including major merger announcements and buyback initiatives from Happiest Minds Technologies and PVR INOX. Milky Mist Dairy showed remarkable profit growth, whereas E2E Networks secured a vital contract.
Comprehensive Section Breakdown for Mankind Pharma
Strategic Vision: Develops, manufactures, and markets pharmaceutical and healthcare products.
• Diverse product portfolio across multiple therapeutic areas.
• Extensive manufacturing, packaging, and marketing capabilities.
Revenue from operations was ₹4,030.59 crore in Q1 FY2026‑27, compared with ₹3,570.35 crore in the same quarter last year and ₹3,442.93 crore in the preceding quarter. The year‑on‑year growth was 12.9%, while the sequential increase of 17.1% followed three quarters of declining revenue.
Profit before tax (PBT) rose to ₹765.51 crore, up 42.5% from ₹537.32 crore a year earlier and 16.7% from ₹656.18 crore in the previous quarter. As a percentage of revenue, PBT improved from 15.0% in Q1 FY2025‑26 to 19.0% in the current quarter, meaning revenue grew faster than total costs before tax.
The tax expense was ₹195.36 crore, up from ₹95.87 crore a year earlier and ₹99.75 crore in the previous quarter. The effective tax rate moved from 17.8% in Q1 FY2025‑26 to 25.5% in the current quarter.
Net profit (profit for the period) came in at ₹574.09 crore, 29.1% higher than the ₹444.62 crore posted a year ago but only 2.6% above the ₹559.42 crore recorded in the preceding quarter. The large increase in the tax expense absorbed much of the pre‑tax profit growth, holding the sequential net profit rise to a small amount.
Category: Manufacturing
This segment addresses both acute and chronic therapeutic areas, offering formulations for conditions such as anti-infectives, cardiovascular diseases, gastrointestinal disorders, anti-diabetic treatments, dermatological issues, erectile dysfunction, and anti-allergic treatments.
Category: Manufacturing
The company also has a significant presence in the consumer healthcare products market, focusing on manufacturing, packaging, and marketing these products.
Core Thesis: The company operates with a strategy of introducing multiple brands within each therapeutic segment to cater to a broad patient population.
• Therapeutic Area Focus: The pharmaceutical segment addresses both acute and chronic therapeutic areas with a diverse product portfolio. • Brand Diversification: A strategy of introducing multiple brands within each therapeutic segment caters to a broad patient population. • Market Reach: The business model focuses on manufacturing, packaging, and marketing products to reach a wide customer base across India.